Trial Profile

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary) ; Insulin
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics
Acronyms EJB051

Most Recent Events

09 Feb 2022 Planned End Date changed from 30 Nov 2022 to 30 Nov 2023.
09 Feb 2022 Planned primary completion date changed from 22 Oct 2022 to 30 Oct 2023.
05 Feb 2020 Planned End Date changed from 1 Oct 2024 to 30 Nov 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com